Oligometastatic status as predictor of survival in metastatic human papillomavirus‐positive oropharyngeal carcinoma
William G. Albergotti(University of Pittsburgh Medical Center), Seungwon Kim(UPMC Hillman Cancer Center), Jonas T. Johnson(University of Pittsburgh), Shira Abberbock(UPMC Hillman Cancer Center), Robert L. Ferris(University of Pittsburgh), Umamaheswar Duvvuri(City University of New York), Fasil Mathews(University of Pittsburgh)
Cited by 36
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590